Biogen Inc Cmn (BIIB) 254.69 $BIIB Krispy Is Kremed; RIP

New Post Public Reply Private Reply Replies (0) Message Board

Mar 26, 2016 at 12:42 AM

Biogen Inc Cmn (BIIB) 254.69 $BIIB

Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), WMT: 68.00 (+0.54), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), AGN: 279.32 (-1.99), SBUX: 58.36 (-0.47), JACK: 63.12 (+0.02), JNJ: 108.31 (-0.19), DNKN: 45.32 (-0.21), IBM: 147.95 (+2.55), CMG: 471.37 (-3.09), ABBV: 56.12 (-0.24), SNY: 38.87 (-0.53), KKD: 14.61 (+0.32), REGN: 370.80 (+5.42), HD: 130.46 (+0.24), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), PLKI: 51.07 (+0.98), DIN: 92.00 (-1.02), CELG: 100.54 (+0.62), QSR: 37.63 (-0.38), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), MCD: 123.29 (-0.90), WEN: 10.42 (+0.06)

Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
at The Street - Fri Mar 25, 9:30AM CDT
A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.
BIIB: 254.69 (-0.55), GILD: 91.32 (+1.24), EDIT: 31.31 (+0.86), MRK: 53.07 (-0.01), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)

Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
Arpita Dutt - Zacks Investment Research - Thu Mar 24, 2:15PM CDT
It was all about patent infringement lawsuits this week in the biotech sector with a couple of high profile jury rulings taking center-stage.
BIIB: 254.69 (-0.55), BMRN: 80.87 (+0.26), KITE: 42.37 (-0.07), GILD: 91.32 (+1.24), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)

AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 254.69 (-0.55), OPHT: 41.09 (+0.69), AVEO: 0.95 (unch), NVS: 73.30 (-0.61)

After Yesterday's Rally of 1.46% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 22, 12:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 254.69 (-0.55)

Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.46%
Comtex SmarTrend(R) - Tue Mar 22, 12:03PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.20 to a high of $260.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $257.41 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 254.69 (-0.55)

Cramer: The Biotech Stocks Are in No Man's Land Right Now
at The Street - Tue Mar 22, 5:17AM CDT
The group rallied yesterday, but it's still not out of the woods.
AGN: 279.32 (-1.99), BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), BMY: 62.52 (+0.18), CELG: 100.54 (+0.62)

Biogen to Report First Quarter 2016 Financial Results on April 21, 2016
Business Wire - Mon Mar 21, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2016 financial results on Thursday, April 21, 2016, before the financial markets open.
BIIB: 254.69 (-0.55)

Stock Market News for March 21, 2016
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 9:10AM CDT
Benchmarks closed in positive territory on Friday following gains in financial services and healthcare stocks.
AMZN: 582.95 (+13.32), BIIB: 254.69 (-0.55), AXP: 60.47 (-0.16), C: 41.94 (-0.43), AMGN: 149.24 (+0.48), MYL: 45.88 (+0.47), ILMN: 155.34 (+2.80), BAC: 13.68 (+0.06), WFC: 48.90 (-0.86), ADBE: 92.52 (+0.36), CELG: 100.54 (+0.62), GS: 153.00 (-1.08), JPM: 59.48 (-0.46), MSFT: 54.21 (+0.24), BHI: 44.68 (-0.28)

Biogen Inc. vs. Amgen: Which Big Biotech Is the Smarter Buy Today?
Brian Feroldi, The Motley Fool - Motley Fool - Mon Mar 21, 8:57AM CDT
Image source: Images_of_Money via Flickr Creative Commons. Biotech blue chips Biogen and Amgen have each been home-run stocks for long-term investors. If you were smart enough to take a small positioning either of these companies five, 10, or...
BIIB: 254.69 (-0.55), AMGN: 149.24 (+0.48)

Zacks Industry Outlook Highlights: Valeant, Pfizer, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 8:30AM CDT
Zacks Industry Outlook Highlights: Valeant, Pfizer, Amgen and Biogen
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), PFE: 30.08 (-0.11), AMGN: 149.24 (+0.48)

Eli Lilly Down, Alters Primary Endpoint of Solanezumab
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:49PM CDT
Eli Lilly (LLY) has changed the primary endpoint of the EXPEDITION3 study on solanezumab for the treatment of mild Alzheimer's dementia.
BIIB: 254.69 (-0.55), AMAG: 21.42 (+0.74), LLY: 71.12 (-0.05), ANIK: 44.00 (-0.74)

Lilly Alzheimer's Study Change Piles Risk on Risk; Jim Cramer Comments
at The Street - Wed Mar 16, 10:16AM CDT
Investors grow concerned about Lilly's decision to alter the primary endpoint for its most important Alzheimer's drug trial. One of those is TheStreet's Jim Cramer.
BIIB: 254.69 (-0.55), LLY: 71.12 (-0.05)

How to Ride the Next Wave of Potential Alzheimer's Drugs
Cory Renauer, The Motley Fool - Motley Fool - Sun Mar 13, 10:04AM CDT
Image source: Biogen. Treating Alzheimer's disease costs the U.S. hundreds of billions each year, but to date there are no drugs to treat its underlying cause. Aducanumab from Biogen and solanezumab from Eli Lilly are arguably the most...
BIIB: 254.69 (-0.55), AZN: 28.00 (-0.01), LLY: 71.12 (-0.05)

Jim Cramer Says He's 'Very Confident' About Salesforce.com
at The Street - Fri Mar 11, 5:37PM CST
TheStreet’s Jim Cramer also discussed several battered biotechs while answering viewer questions from social media on Friday.
KO: 45.58 (+0.12), BIIB: 254.69 (-0.55), DLTR: 78.52 (-0.44), AMGN: 149.24 (+0.48), ORCL: 40.97 (+0.22), REGN: 370.80 (+5.42), PEP: 100.68 (-0.13), CRM: 72.44 (+0.66), CELG: 100.54 (+0.62)

Better Buy: Amgen Inc. vs. Biogen
Cory Renauer, The Motley Fool - Motley Fool - Thu Mar 10, 9:44AM CST
Biotechnology pioneers Biogen and Amgen have taken a beating from the market this year. On the bright side they've suffered less than their smaller peers in the NASDAQ Biotechnology ETF , which as a whole has underperformed both stocks. ...
BIIB: 254.69 (-0.55), AMGN: 149.24 (+0.48)

Better Big Biotech Stock: Biogen vs. Celgene
Michael Douglass, The Motley Fool - Motley Fool - Tue Mar 08, 8:04AM CST
Photo credit: Pixabay via Flickr. Biogen and Celgene are both excellent companies, and I'm a proud shareholder of both. But in a battle between these two excellent growth stocks (which I view as two cornerstones to any new healthcare...
BIIB: 254.69 (-0.55), CELG: 100.54 (+0.62)

Flex Pharma Reports Year End 2015 Financial Results
Business Wire - Tue Mar 08, 6:00AM CST
Click to Tweet
BIIB: 254.69 (-0.55), FLKS: 10.48 (-0.92)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...